Display options
Cite
Khamisi S, Lundqvist M, Emadi P, et al. Serum thyroglobulin is associated with orbitopathy in Graves' disease. J Endocrinol Invest. 2021;44(9):1905-1911doi: 10.1007/s40618-021-01505-8.
Khamisi, S., Lundqvist, M., Emadi, P., Almby, K., Ljunggren, �. �., & Karlsson, F. A. (2021). Serum thyroglobulin is associated with orbitopathy in Graves' disease. Journal of endocrinological investigation, 44(9), 1905-1911. https://doi.org/10.1007/s40618-021-01505-8
Khamisi, S, et al. "Serum thyroglobulin is associated with orbitopathy in Graves' disease." Journal of endocrinological investigation vol. 44,9 (2021): 1905-1911. doi: https://doi.org/10.1007/s40618-021-01505-8
Khamisi S, Lundqvist M, Emadi P, Almby K, Ljunggren Ö, Karlsson FA. Serum thyroglobulin is associated with orbitopathy in Graves' disease. J Endocrinol Invest. 2021 Sep;44(9):1905-1911. doi: 10.1007/s40618-021-01505-8. Epub 2021 Jan 29. PMID: 33515213; PMCID: PMC8357771.
Copy Download .nbib Format: NLM
Share it on

J Endocrinol Invest. 2021 Sep;44(9):1905-1911. doi: 10.1007/s40618-021-01505-8. Epub 2021 Jan 29.

Serum thyroglobulin is associated with orbitopathy in Graves' disease.

Journal of endocrinological investigation

S Khamisi, M Lundqvist, P Emadi, K Almby, Ö Ljunggren, F A Karlsson

Affiliations

  1. Department of Endocrinology and Diabetes, Uppsala University Hospital, 751 85, Uppsala, Sweden. [email protected].
  2. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. [email protected].
  3. Department of Endocrinology and Diabetes, Uppsala University Hospital, 751 85, Uppsala, Sweden.
  4. Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  5. Department of Ophthalmology, Uppsala University Hospital, Uppsala, Sweden.

PMID: 33515213 PMCID: PMC8357771 DOI: 10.1007/s40618-021-01505-8

Abstract

PURPOSE: Serum thyroglobulin levels are often elevated in Graves' disease (GD) and in most cases decrease during treatment. Its relation to Graves' orbitopathy (GO) has not been clarified. Previously, a risk of GO has been linked to smoking, TSH receptor stimulation, high TSH-receptor antibodies (TRAb), low thyroid peroxidase and thyroglobulin antibodies (TPOAb, TgAb).

METHODS: We examined Tg levels in 30 consecutive patients with GD were given drug therapy (methimazole + thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. 17 patients had GO, 11 of whom had it at diagnosis while 6 developed GO during treatment. During the study, 5 subjects were referred to radioiodine treatment, 3 to surgery. The remaining 22 subjects (GO n = 12, non-GO n = 10) completed the drug regimen.

RESULTS: At diagnosis, Tg levels in GO patients (n = 11) were higher (84, 30-555 µg/L, median, range) than in non-GO patients (n = 19) (38, 3.5-287 µg/L), p = 0.042. Adding the 6 subjects who developed eye symptoms during treatment to the GO group (n = 17), yielded p = 0.001 vs. non-GO (n = 13). TRAb tended to be higher, while TPOAb and TgAb tended to be lower in the GO group. For the 22 patients who completed the drug regimen, Tg levels were higher in GO (n = 12) vs. non-GO (n = 10), p = 0.004, whereas TRAb levels did not differ.

CONCLUSION: The data may suggest that evaluation of thyroglobulin levels in GD could contribute to identify patients at increased risk of developing GO. Possibly, thyroidal release of Tg in GD reflects a disturbance that also impacts retroorbital tissues.

© 2021. The Author(s).

Keywords: Graves’ disease; Graves’ ophthalmopathy; Graves’ orbitopathy; Thyroglobulin

References

  1. Metabolism. 1978 Apr;27(4):449-60 - PubMed
  2. J Cell Physiol. 1987 Oct;133(1):37-45 - PubMed
  3. Thyroid. 1991 Winter;1(4):293-9 - PubMed
  4. Thyroidology. 1993 Apr;5(1):13-20 - PubMed
  5. J Comput Assist Tomogr. 1979 Dec;3(6):815-9 - PubMed
  6. J Endocrinol Invest. 2004 Mar;27(3):230-6 - PubMed
  7. Clin Endocrinol (Oxf). 2004 May;60(5):600-7 - PubMed
  8. Eur Thyroid J. 2016 Mar;5(1):9-26 - PubMed
  9. N Engl J Med. 2010 Feb 25;362(8):726-38 - PubMed
  10. Eur J Endocrinol. 1999 Jan;140(1):7-8 - PubMed
  11. Eur J Endocrinol. 1999 May;140(5):457-67 - PubMed
  12. Thyroid. 1999 Dec;9(12):1175-80 - PubMed
  13. Expert Opin Ther Targets. 2017 Apr;21(4):427-432 - PubMed
  14. Invest Ophthalmol Vis Sci. 1992 May;33(6):2037-42 - PubMed
  15. Endocrinology. 1985 Jul;117(1):114-8 - PubMed
  16. J Formos Med Assoc. 1991 Dec;90(12):1155-62 - PubMed
  17. Scott Med J. 1974 Jul;19(4):165-9 - PubMed
  18. J Endocrinol Invest. 2016 Dec;39(12):1445-1451 - PubMed
  19. Arch Intern Med. 1985 Feb;145(2):243-7 - PubMed
  20. J Clin Endocrinol Metab. 2006 Sep;91(9):3464-70 - PubMed
  21. Endocr Pract. 2020 Jan;26(1):97-106 - PubMed
  22. J Clin Endocrinol Metab. 2004 May;89(5):2242-7 - PubMed
  23. Endocrinology. 1991 Oct;129(4):2202-11 - PubMed
  24. J Endocrinol Invest. 1980 Jul-Sep;3(3):283-92 - PubMed
  25. Am J Med. 1990 Aug;89(2):175-80 - PubMed
  26. J Clin Endocrinol Metab. 1978 May;46(5):747-55 - PubMed
  27. Eye (Lond). 2007 Sep;21(9):1135-45 - PubMed
  28. Thyroid. 2002 Oct;12(10):855-60 - PubMed
  29. Exp Clin Endocrinol Diabetes. 2014 Feb;122(2):113-7 - PubMed

Publication Types